Danielle Gilliam on FDA’s Approval of Wegovy Pill from Novo Nordisk
Danielle Gilliam, Executive Medical Science Liaison Cardiovascular and Renal at Novo Nordisk North America, shared on LinkedIn:
”The FDA’s approval also clears the pill for use to reduce the risk of major cardiovascular events, such as death, heart attack or stroke, in adults with obesity and established cardiovascular disease, according to Novo Nordisk.”
Find more here.
Read the full announcement by Novo Nordisk here.
Novo Nordisk announced that the US Food and Drug Administration has approved the Wegovy pill, a once-daily oral semaglutide 25 mg, for long-term weight reduction and maintenance, as well as for reducing the risk of major adverse cardiovascular events.
The oral formulation is indicated for adults with obesity or overweight who have at least one weight-related comorbidity, and for adults with established heart disease to lower the risk of death, heart attack, or stroke.
In addition, Wegovy injection is approved for chronic weight management in paediatric patients aged 12 years and older.
The injectable form is also approved for the treatment of MASH in adults with moderate to advanced liver fibrosis, excluding those with cirrhosis.
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026